Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions

Cdc2-like kinases (CLKs; CLK1–4) are associated with various neurodegenerative disorders, metabolic regulation, and viral infection and have been recognized as potential drug targets. Human CLK2 has received increasing attention as a regulator that phosphorylates serine- and arginine-rich (SR) prote...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medicinal chemistry 2021-09, Vol.64 (18), p.13191-13211
Hauptverfasser:	Qin, Zhen, Qin, Lian, Feng, Xi, Li, Zhiyu, Bian, Jinlei
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Line, Tumor Clinical Trials as Topic Enzyme Assays HEK293 Cells Humans Neoplasms - drug therapy Osteoarthritis - drug therapy Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein Serine-Threonine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!